A liquid biopsy test that profiles blood-based biomarkers to help guide cancer treatment decisions.
Consented intake · your records travel with you · nothing moves without your sign-off
Guardant 360 CDx is a liquid biopsy test that gathers and analyzes blood and other bodily fluids for biomarkers including DNA, RNA, and proteins. It is designed to surface distinctive markers that can guide treatment and monitor disease progression, covering minimum residual disease monitoring and early detection for patients tracking their cancer.
Prefer the source? Guardant 360 CDx's own site has more.
The fastest way to know what you'll pay: check your coverage with your plan. Below is what we know about how Guardant 360 CDx handles billing.
We don't have confirmed insurance details for Guardant 360 CDx yet. Start a coverage check with your plan, or contact the provider directly.
Answers grounded in Guardant's details here. Educational only; your oncologist directs treatment.
Powered by Navis on opencancer.ai
Other providers in similar categories.
Gather distinctive biomarkers that can guide treatment and monitor disease progression
FoundationOne CDx is an FDA-approved comprehensive genomic profiling test that analyzes 324 genes to identify clinically relevant genomic alterations.
Tempus xT is a comprehensive genomic profiling test combining DNA and RNA sequencing to identify actionable mutations.
Matches your tumor's biomarkers to the therapies most likely to work for you — mapping your molecular profile to targeted and approved options.
This page is general information. Upload your records for analysis specific to YOUR diagnosis.